Albendazole is an antihelminthic agent belonging to the benzimidazole class and has been used successfully in the treatment of neurocysticercosis. We report here a method for the determination of the two major albendazole metabolites in plasma, albendazole sulfone and albendazole sulfoxide. The method consists of drug extraction from 500 microL of plasma previously acidified with chloroform-isopropanol (9:1, v/v) and extract purification with n-hexane immediately before chromatographic analysis. Separation of drugs and of the internal standard (mebendazole) was performed on an RP-18 column using acetonitrile-0.25N sodium acetate buffer (3:7, v/v), pH 5.0, as the mobile phase and using detection at 290 nm.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jat/18.2.86 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tea Saponins: a Novel Stabilizer for Enhancing the Oral Bioavailability of Albendazole Nanocrystals.
AAPS PharmSciTech
January 2025
School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Albendazole serves as a broad-spectrum anthelmintic medication for treating hydatid cysts and neurocysticercosis. However, its therapeutic effectiveness is limited by poor solubility. Nanocrystals offer a promising technology to address this limitation by enhancing drug solubility.
View Article and Find Full Text PDFPharmacokinetics and Tissue Distribution of Albendazole and Its Three Metabolites in Yellow River Carp () after Single Oral Administration.
J Agric Food Chem
January 2025
Laboratory of Veterinary Drug Development and Evaluation, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
This study aimed to evaluate the pharmacokinetics and tissue distribution of albendazole (ABZ) and its three metabolites─albendazole sulfoxide (ABZSO), albendazole sulfone (ABZSO), and albendazole-2-aminosulfone (ABZ-2-NH-SO)─in Yellow River carp () reared at 17.2 ± 1.1 °C after single oral administration of 12 mg/kg body weight (BW) ABZ.
View Article and Find Full Text PDFInvestigation of a fully mechanistic physiologically based pharmacokinetics model of absorption to support predictions of milk concentrations in breastfeeding women and the exposure of infants: A case study for albendazole.
CPT Pharmacometrics Syst Pharmacol
November 2024
Medicines and Healthcare Products Regulatory Agency, London, UK.
Article Synopsis
- European guidelines advise against breastfeeding while using albendazole due to limited data.
- A study utilized PBPK modeling to estimate albendazole and its metabolite's concentrations in plasma and breast milk of nursing mothers.
- The model indicated lower exposure risks for infants through breast milk, but additional clinical data is necessary for more accurate predictions.
Application potential of albendazole as an aquatic animal drug based on its safety, efficacy, and residue profiles.
Toxicol Res
October 2024
Pesticide and Veterinary Drug Residues Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Chungcheongbuk-do 28159 Republic of Korea.
Article Synopsis
- The lack of adequate drug options for treating parasites in aquatic animals has led researchers to explore the repurposing of existing livestock drugs, particularly albendazole (ABZ), which has shown effectiveness in various species.* -
- Toxicological studies revealed that ABZ depletes quickly from muscle tissues of several fish but may cause toxicity at high doses, similar to effects seen in humans and other animals.* -
- Efficacy trials demonstrated that ABZ can effectively treat parasites in species like eels and shrimp, making it a potentially valuable alternative for fish farmers facing high demands for new veterinary drugs in aquaculture.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!